Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1136/postgradmedj-2021-139923 http://scihub22266oqcxt.onion/10.1136/postgradmedj-2021-139923 33850011!?!33850011 Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=33850011&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Postgrad+Med+J 2022 ; 98 (1159): 395-402 Nephropedia Template TP {{tp|p=33850011|t=2022. Anticoagulation in COVID-19: current concepts and controversies |pdf=|usr=}}{{33850011}} gab.com Text Anticoagulation in COVID-19: current concepts and controversies JO: Postgrad Med J http://www.kidney.de/pget.php?&tw=1&pmid=33850011 #FOAvip Rising incidence of thromboembolism secondary to COVID-19 has become a global concern, with several surveys reporting increased mortality rates. Thrombogenic potential of the SARS-CoV-2 virus has been hypothesised to originate from its ability to produce an exaggerated inflammatory response leading to endothelial dysfunction. Anticoagulants have remained the primary modality of treatment of thromboembolism for decades. However, there is no universal consensus regarding the timing, dosage and duration of anticoagulation in COVID-19 as well as need for postdischarge prophylaxis. This article seeks to review the present guidelines and recommendations as well as the ongoing trials on use of anticoagulants in COVID-19, identify discrepancies between all these, and provide a comprehensive strategy regarding usage of these drugs in the current pandemic. Twit Text FOAVip Anticoagulation in COVID-19: current concepts and controversies ????Postgrad Med J http://www.kidney.de/pget.php?&tw=1&pmid=33850011 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33850011 #FOAvip English Wikipedia <ref>{{Cite pmid|33850011}}</ref> Anticoagulation in COVID-19: current concepts and controversies #MMPMID33850011 Chandra A; Chakraborty U; Ghosh S; Dasgupta S Postgrad Med J 2022[May]; 98 (1159): 395-402 PMID33850011show ga Rising incidence of thromboembolism secondary to COVID-19 has become a global concern, with several surveys reporting increased mortality rates. Thrombogenic potential of the SARS-CoV-2 virus has been hypothesised to originate from its ability to produce an exaggerated inflammatory response leading to endothelial dysfunction. Anticoagulants have remained the primary modality of treatment of thromboembolism for decades. However, there is no universal consensus regarding the timing, dosage and duration of anticoagulation in COVID-19 as well as need for postdischarge prophylaxis. This article seeks to review the present guidelines and recommendations as well as the ongoing trials on use of anticoagulants in COVID-19, identify discrepancies between all these, and provide a comprehensive strategy regarding usage of these drugs in the current pandemic. |*COVID-19[MESH] |*Thromboembolism/drug therapy/etiology/prevention & control[MESH] |*Venous Thromboembolism/etiology[MESH] |Aftercare[MESH] |Anticoagulants/therapeutic use[MESH] |Humans[MESH] |Patient Discharge[MESH]Anticoagulation in COVID-19: current concepts and controversies (epmc).pdf DeepDyve Pubget Overpricing